Clinical Trial

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2025 (before its estimated June 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research is to evaluate the efficacy and the safety of two doses of ZSP1601 for 48 weeks versus placebo in adult NASH patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-10; most recent amendment 2025-03-18.
Status change: Recruiting → Active, Not Recruiting 2025-03-18
Status change: Not Yet Recruiting → Recruiting 2023-06-06
Trial Details
NCT Number NCT05692492
Lead Sponsor Guangdong Raynovent Biotech Co., Ltd
Conditions Nonalcoholic Steatohepatitis (NASH)
Enrollment 180 participants
Start Date 2023-06-03
Primary Completion 2026-06-16 (estimated)
Study Completion 2026-12-16 (estimated)
Updated on ClinicalTrials.gov 2025-03-19